LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial
John B.A.G. Haanen, M. Rohaan, T.H. Borch, J.H. van den Berg, Ö. Met, Marnix Geukes Foppen, J. Stoltenborg Granhøj, B. Nuijen, C. Nijenhuis, J.H. Beijnen, I. Jedema, M. van Zon, I.M. Noringriis, R. Kessels, S. Wilgenhof, H.V. van Thienen, F. Lalezari, Alexander C. J. van Akkooi, Marco Donia, Inge Marie Svane
Topics & Concepts
MedicineIpilimumabMelanomaOncologyInternal medicineTumor-infiltrating lymphocytesRandomized controlled trialImmunotherapyCancer researchCancerCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses